• Text size
  • Send this article to a friend
  • Print this article

Glaxo faces up to tough competition

Glaxosmithkline yesterday reported a 5% increase in fourth-quarter earnings but forecast that earnings growth would dip this year, despite the introduction of several products, as competition from generic drugs intensifies.

Glaxosmithkline yesterday reported a 5% increase in fourth-quarter earnings but forecast that earnings growth would dip this year, despite the introduction of several products, as competition from generic drugs intensifies.